Clicky

Paradigm Biopharmaceuticals Ltd(PAR)

Description: Paradigm Biopharmaceuticals Limited is a biopharmaceutical company focused on repurposing the drug pentosan polysulfate sodium (PPS) for the treatment of inflammation. The Company is engaged in researching and developing therapeutic products for human use. The Company is a drug repurposing company, which seeks to find new uses for old drugs. The Company has commenced the open labelled Phase II clinical trial, investigating the role of the drug PPS in treating traumatic Bone Marrow Lesions. The Company's Rhinosul has properties consisting of both histamine stabilizing and anti-inflammatory properties. The Company focuses on repurposing PPS under ZILOSUL name, as a treatment for bone marrow edema (BME) lesions following traumatic injury.


Keywords: Pharmaceutical Biopharmaceutical Drugs Medication Organ Systems Inflammation Clinical Trial Therapeutic Products Bone Marrow Osteochondritis Dissecans Traumatic Injury Pentosan Polysulfate

Home Page: www.paradigmbiopharma.com

PAR Technical Analysis

T. Rowe Price Retirement Funds, Inc.
,

Phone: 61 3 9629 5566


Officers

Name Title
Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC Founder, MD & Exec. Chairman
Dr. Donna L. Skerrett M.D., MS Chief Medical Officer and Exec. Director
Mr. Justin Cahill Chief Financial Officer
Dr. Ravi Krishnan Chief Scientific Officer
Mr. Simon White Director of Investor Relations
Dr. Michael Imperiale Global Head of Drug Safety & MPS
Ms. Beverley Huttmann Commercial Head
Ms. Michelle Coffey Global Head of Regulatory Affairs
Dr. Mukesh Ahuja Global Clinical Head of OA
Mr. Marco Polizzi Exec. Officer

Exchange: AU

Country: AU

Currency: Australian Dollar (A$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 8.8239
Price-to-Sales TTM: 4676.7607
IPO Date:
Fiscal Year End: June
Full Time Employees: 0
Back to stocks